recombinant factor VIII Fc fusion protein; recombinant antihemophilic factor Fc fusion protein; recombinant antihemophilic factor Fc-VWF-XTEN fusion protein-ehtl (Eloctate, Altuviiio)

^[1]^[2]^[3]

Indications

prophylaxis
- Eloctate
  - start: 50 IU/kg every four days
  - maintenance: 25 to 65 IU/kg and every three to five days.
- Altuviiioa: weekly^[3]

↑ FDA News Release. June 6, 2014 FDA approves the first antihemophilic factor, Fc fusion protein for patients with Hemophilia A. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm400167.htm
↑ biogen idec. Press Release. June 6, 2014 FDA Approves Biogen Idec's s ELOCTATE, First Hemophilia A Therapy to Extend the Interval between Prophylactic Infusions, for Both Adults and Children. http://www.biogenidec.com/press_release_details.aspx?ID=14712&Action=1&NewsId=2338&M=NewsV2&PID=61997
↑ ^3.0 ^3.1 Bassett M FDA Approves Weekly Factor Therapy for Hemophilia A. Factor VIII replacement therapy provides protection from bleeds with once-weekly dosing. MedPage Today February 23, 2023 https://www.medpagetoday.com/hematologyoncology/hemophilia/103246